Johnson & Johnson/$JNJ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Ticker
$JNJ
Sector
Primary listing
NYSE
Employees
138,100
Headquarters
Website
JNJ Metrics
BasicAdvanced
$455B
18.25
$10.35
0.39
$5.08
2.75%
Price and volume
Market cap
$455B
Beta
0.39
52-week high
$194.48
52-week low
$140.68
Average daily volume
8.5M
Dividend rate
$5.08
Financial strength
Current ratio
1.074
Quick ratio
0.711
Long term debt to equity
49.709
Total debt to equity
57.766
Dividend payout ratio (TTM)
48.70%
Interest coverage (TTM)
27.44%
Profitability
EBITDA (TTM)
32,480
Gross margin (TTM)
68.42%
Net profit margin (TTM)
27.26%
Operating margin (TTM)
26.62%
Effective tax rate (TTM)
20.26%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
8.26%
Return on equity (TTM)
33.62%
Valuation
Price to earnings (TTM)
18.252
Price to revenue (TTM)
4.934
Price to book
5.73
Price to tangible book (TTM)
-23.34
Price to free cash flow (TTM)
24.34
Free cash flow yield (TTM)
4.11%
Free cash flow per share (TTM)
7.76
Dividend yield (TTM)
2.69%
Forward dividend yield
2.75%
Growth
Revenue change (TTM)
5.08%
Earnings per share change (TTM)
71.26%
3-year revenue growth (CAGR)
2.79%
10-year revenue growth (CAGR)
2.71%
3-year earnings per share growth (CAGR)
12.96%
10-year earnings per share growth (CAGR)
7.10%
3-year dividend per share growth (CAGR)
5.07%
10-year dividend per share growth (CAGR)
5.77%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
Bulls say / Bears say
Johnson & Johnson exceeded second-quarter earnings expectations with adjusted EPS at $2.77, higher than the $2.68 forecast, and posted revenue of $23.74 billion, beating the estimated $22.84 billion. As a result, management raised full-year sales projections to $93.2–93.6 billion and updated its adjusted EPS forecast to $10.80–10.90 (Reuters).
The U.S. Food and Drug Administration has approved Inlexzo (TAR-200) for high-risk non-muscle invasive bladder cancer in patients unresponsive to BCG therapy. This decision was based on a mid-stage trial where more than 82% of patients were cancer-free at three months and over half remained disease-free after one year, expanding J&J’s oncology product line (Reuters).
J&J’s MedTech division achieved strong unit sales growth of 6.1% to $8.54 billion in Q2, surpassing analysts’ consensus of $8.25 billion, highlighting the robust and diversified performance of its medical devices segment (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
JNJ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Johnson & Johnson stock?
Johnson & Johnson (JNJ) has a market cap of $455B as of November 02, 2025.
What is the P/E ratio for Johnson & Johnson stock?
The price to earnings (P/E) ratio for Johnson & Johnson (JNJ) stock is 18.25 as of November 02, 2025.
Does Johnson & Johnson stock pay dividends?
Yes, the Johnson & Johnson (JNJ) stock pays dividends to shareholders. As of November 02, 2025, the dividend rate is $5.08 and the yield is 2.75%. Johnson & Johnson has a payout ratio of 48.7% on a trailing twelve-month basis.
When is the next Johnson & Johnson dividend payment date?
The next Johnson & Johnson (JNJ) dividend payment is scheduled for December 09, 2025.
What is the beta indicator for Johnson & Johnson?
Johnson & Johnson (JNJ) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.